2022
DOI: 10.1136/bmjopen-2021-057803
|View full text |Cite
|
Sign up to set email alerts
|

Cost analysis and cost-effectiveness of open versus laparoscopic versus robot-assisted versus transanal total mesorectal excision in patients with rectal cancer: a protocol for a systematic review

Abstract: IntroductionNowadays, most rectal tumours are treated open or minimally invasive, using laparoscopic, robot-assisted or transanal total mesorectal excision. However, insight into the total costs of these techniques is limited. Since all three techniques are currently being performed, including cost considerations in the choice of treatment technique may significantly impact future healthcare costs. Therefore, this systematic review aims to provide an overview of evidence regarding costs in patients with rectal… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 16 publications
0
3
0
Order By: Relevance
“…This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement and in line with the protocol agreed by all authors [18]. The study protocol was written in accordance with the PRISMA-P statement and registered in the International prospective register of systematic reviews (Prospero).…”
Section: Methodsmentioning
confidence: 99%
“…This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement and in line with the protocol agreed by all authors [18]. The study protocol was written in accordance with the PRISMA-P statement and registered in the International prospective register of systematic reviews (Prospero).…”
Section: Methodsmentioning
confidence: 99%
“…On the other hand, to our best knowledge, no study has compared the cost‐effectiveness of robotic TME with that of taTME. Currently, several systematic reviews and prospective studies are underway to clarify such cost‐effectiveness 45,46 …”
Section: Short‐ and Middle‐term Oncologic Outcomes After Tatmementioning
confidence: 99%
“…Currently, several systematic reviews and prospective studies are underway to clarify such costeffectiveness. 45,46 Current status and future perspective of taTME in Japan…”
Section: Cost-effectiveness Of Tatmementioning
confidence: 99%